Edition:
United Kingdom

OncoMed Pharmaceuticals Inc (OMED.OQ)

OMED.OQ on NASDAQ Stock Exchange Global Select Market

2.16USD
22 Feb 2018
Change (% chg)

$-0.07 (-3.14%)
Prev Close
$2.23
Open
$2.24
Day's High
$2.24
Day's Low
$2.10
Volume
42,876
Avg. Vol
60,303
52-wk High
$10.86
52-wk Low
$1.75

Chart for

About

OncoMed Pharmaceuticals, Inc. (OncoMed) is a clinical-stage biopharmaceutical company. The Company focuses on discovering and developing therapeutics that address the fundamental biology driving cancer's growth, resistance, recurrence and metastasis. The Company's therapeutic candidates and preclinical programs include... (more)

Overall

Beta: 2.74
Market Cap(Mil.): $164.07
Shares Outstanding(Mil.): 37.63
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 83.93 16.60
EPS (TTM): -- -- --
ROI: -- 1.66 10.66
ROE: -- 2.58 14.30

BRIEF-Oncomed Says Chief Executive Officer Paul Hastings Has Resigned

* ONCOMED ANNOUNCES CHAIRMAN, PRESIDENT AND CHIEF EXECUTIVE OFFICER PAUL J. HASTINGS HAS RESIGNED

04 Jan 2018

BRIEF-OncoMed Estimates 2018 Operating Cash Burn To Be Less Than $55 Mln

* ONCOMED PROVIDES 2018 OUTLOOK AND 2017 YEAR-END CASH BALANCE AND ANNOUNCES AN UPDATE ON THE ROSMANTUZUMAB PROGRAM

04 Jan 2018

BRIEF-Perceptive Advisors reports 6.5 pct passive stake in Oncomed Pharmaceuticals

* PERCEPTIVE ADVISORS LLC REPORTS A 6.5 PCT PASSIVE STAKE IN ONCOMED PHARMACEUTICALS INC AS OF NOV 6 - SEC FILING Source text: [http://bit.ly/2nzZrC0] Further company coverage:

06 Dec 2017

BRIEF-Oncomed says CEO Paul Hastings to Resume Chairman of Board Responsibilities

* ONCOMED - ‍CHAIRMAN, PRESIDENT, CEO PAUL HASTINGS WILL RESUME CHAIRMAN OF BOARD RESPONSIBILITIES, EFFECTIVE DEC. 4, 2017​

27 Nov 2017

BRIEF-Oncomed posts Q3 loss per share $0.28

* Oncomed announces third quarter 2017 financial results and operational highlights

02 Nov 2017

BRIEF-OncoMed CEO Paul Hastings to take medical leave of absence

* OncoMed chairman and CEO, Paul Hastings, to take medical leave of absence

19 Sep 2017

BRIEF-OncoMed doses first patient with GITRL-Fc in phase 1a clinical trial

* OncoMed doses first patient with GITRL-Fc in phase 1a clinical trial Source text for Eikon: Further company coverage:

13 Sep 2017

Earnings vs. Estimates